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Summary. Parkinson's disease (PD) is characterised by the progressive 
degeneration of nigrostriatal dopamine (DA) neurons resulting in the major 
symptoms of akinesia and rigidity. Although the primary cause of PD is still 
not known some features make this disorder a model for neurodegenerative 
diseases in general. It has been known for some time that symptomatic PD 
can be attributed to insults with symptoms occurring many years later such 
as postencephalitic PD or PD following manganese poisoning. More re-
cently, MPTP (l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine) has been 
identified as a neurotoxin selective for melanin-containing dopaminergic 
neurons in humans and non-human primates. The specificity of this neu-
rotoxin and the striking clinical similarities to idiopathic PD, seen in 
primates, make MPTP-induced parkinsonism the most useful animal model 
of a neurological disease. There are numerous theoretical possibilities to 
interfere with both MPTP-induced neurotoxicity and the symptomatology of 
PD. In recent years excitatory amino acids have gained considerable 
interest since they can cause excitotoxic lesion of neurons under a number 
of pathological conditions (Olney et al., 1989; Choi, 1988). Here we 
summarise the present data and provide new experimental evidence in-
dicating that MPTP-induced degeneration of dopaminergic neurons does 
involve glutamate-mediated toxicity. It is concluded that glutamate-mediated 
excitotoxicity results in the destruction of DAergic somata in the substantia 
nigra. Non-competitive or competitive N M D A antagonists protect nigral 
neurons from MPTP-induced degeneration whereas their striatal terminals 
still seem to degenerate. 
Exitatory amino acids ( E A A ) such as L-glutamate or L-aspartate have 
been identified as transmitters in the mammalian central nervous system 
(Fonnum, 1984; Watkins et al., 1990). Biochemical, electrophysiological 
and neuroanatomical studies indicate that both amino acids, beside their 
metabolic functions, could serve as neuro transmitters. E A A s are released 
from slices or synaptosome preparations in a calcium-dependent fashion and 
are accumulated by a high-affinity uptake system. Upon release E A A s act 
as depolarizing agents by activating ionophore-coupled glutamate recep-
tors divided pharmacologically into three subtypes. N-methyl-D-aspartate 
( N M D A ) , quisqualate (QUIS) or a-amino-3-hydroxy-5-methyl-4-isoxazole-
propionate ( A M P A ) and kainate (KAIN) act as agonists on these receptors. 
Additionally, two G protein-coupled E A A receptors have been identified. 
The metabotropic receptor, linked to phospholipase C, is activated by trans-
l-aminocyclopentane-l,3-dicarboxylate (ACPD) . Stimulation of this subtype 
causes an increased inositol-l,4,5-triphosphate (IP3) synthesis and a sub-
sequent rise in intracellular calcium levels. Finally, there is a less well-
defined receptor, activated by L-2-amino-4-phosphobutyrate (L-AP4), which 
may be located presynaptically and inhibits transmitter release, again via a 
presumably G protein-mediated process. Molecular biology revealed the 
structure of E A A receptors, encoded by a variety of separate genes. 
Neurodegenerative diseases such as Alzheimer's, Parkinson's and Hun-
tington's diseases or amyotrophic lateral sclerosis have been related to 
dysfunction of glutamatergic systems (Olney, 1989). L-glutamate itself 
(Olney, 1969) and compounds activating E A A receptors coupled to iono-
phores have neurotoxic properties and can produce excitotoxic lenions 
which morphologically resemble human neurodegenerative disorders 
(Horowski et al., 1994). Under a variety of experimental conditions N M D A 
or glutamate mediated toxicity is blocked by competitive or non-competitive 
N M D A receptor antagonists such as 3-((±)-2-carboxypiperazin-4-yl)-propyl-
1-phosphonic acid (CPP) or (+)-5-metyl-10,ll-dihydro-5H-dibenzo-
(a,d)cyclohepten-5,10-imine maleate (MK-801) in-vitro and in-vivo. Here 
we discuss experimental evidence linking MPTP or l-methyl-4-
phenylpyridinium ion ( M P P + ) mediated toxicity to E A A s . 
Following systemic administration the neurotoxin MPTP produces a 
parkinsonian syndrome in humans and non-human primates (Davis et al., 
1979; Langston et al., 1983; Burns et al., 1983). Similar to the observed 
histopathological features in Parkinson's disease (PD), dopaminergic neu-
rons of the substantia nigra pars compacta (SNc) are primarily destroyed by 
the toxin (Burns et al., 1983), although other populations of cells are also 
affected to some degree (Perez-Otano et al., 1991). Thus, at least in pri-
mates, MPTP-induced neurodegeneration provides the animal model closest 
to PD that is currently available. However, there are histopathological and 
probably pathophysiological differences between the disease and the model 
situation in experimental animals. In addition, MPTP-induced cell death is 
an acute insult with symptoms occuring within hours to weeks whereas PD 
slowly progresses over years and some of the human histopathological 
features such as Lewy bodies, are rarely seen in brains of MPTP-treated 
primates (Forno et al., 1986). Nevertheless, the MPTP model in primates 
and, for practical reasons, in rodents offers the unique opportunity to study 
mechanisms involved in the destruction of dopa-minergic neurons. A better 
understanding of the pathophysiology of MPTP could result in the develop-
ment of strategies to protect cells and hopefully in preventive treatments of 
PD and other neurodegenerative diseases. Despite the intensive research in 
recent years the precise mechanisms mediating the neurotoxicity of MPTP 
are not known although some crucial requirements are well established. 
MPTP readily passes the blood brain barrier. Probably in glial cells or 
non-dopaminergic neurons, MPTP is then oxidized to l-methyl-4-
phenyldihydropyridine (MPDP) which in turn is converted by monoamine 
oxidase type B (MAO-B) into the neurotoxic M P P + (Castagnoli et al., 
1985). The latter compound is accumulated in dopaminergic cells by the 
high affinity D A uptake carrier and temporarily stored in a releasable pool 
(Javitch et al., 1985; Schinelli et al., 1988). In addition M P P + binds with 
high affinity to neuromelanin (D'Amato et al., 1986). Several mechanisms 
have been proposed to explain the toxicity at the cellular level. M P P + is 
taken up intraneuronally by a mitochondrial carrier and inhibits complex I 
of the mitochondrial respiratory chain (Nicklas et al., 1985), resulting in a 
rapid cellular adenosinetriphosphate- (ATP) depletion (Chan et al., 1991) 
and subsequent cell death. This observation is of particular importance 
since an age-related reduction of complex I activity is observed in primates 
(Di Monte et al., 1993) and in post mortem brain tissue obtained from PD 
patients (Schapira et al., 1990). In addition, M P P + could catalyse the 
formation of free radical species, resulting in oxidative cell damage (Lai et 
al., 1993) and M P P + induces apoptosis (Dipasquale et al., 1991). 
Experimental evidence suggests an involvement of E A A s such as gluta-
mate within the neuropathological cascade of MPTP/MPP + -induced cell 
death. M P P + induces in rats a release of glutamate and aspartate (Carboni 
et al., 1990) and a massive release of D A and lactate when delivered 
through a dialysis probe to the brain (Rollema et al., 1988). In addition we 
have shown that the neurotoxic properties of M P P + following focal in-
jection into the substantia nigra of rats are blocked by systemic treatment 
with non-competivie and competitive antagonist of N M D A receptors such 
as MK-801 or CPP, respectively (Turski et al., 1991). This report caused a 
controversial discussion with respect to the methods employed (Sonsalla et 
al., 1992). High local concentrations of M P P + resulting from its focal 
administration to the brain could possibly produce unspecific toxic effects 
(Harik et al., 1987). It was therefore of importance to test whether this 
observation was restricted to the focal administration of M P P + or whether 
it occurred following systemic treatment with MPTP. Since rats are not 
sensitive to MPTP, common marmosets were treated with MPTP alone and 
in combination with the competitive NMDA-antagonist CPP for up to two 
days. A t post mortem the monoamine and metabolite content in the 
putamen were measured and a quantitative histological analysis of tyrosine 
hydroxylase (TH) positive neurons in the substantia nigra pars compacta 
was performed. MPTP-treatment resulted in a massive loss of intact T H -
positive neurons in the substantia nigra, whereas CPP completely protected 
these cells. However, under the experimental conditions employed here, 
striatal levels of dopamine and its metabolites D O P A C and H V A were 
reduced (Lange et al., 1993). In line with these findings Zuddas et al. (1992) 
reported on the neuroprotective effects of MK-801 in another monkey 
species (M. fascicularis). Again, in animals treated with both MPTP and 
MK-801 nigral T H positive neurones were preserved, whereas striatal 
dopamine and — to a larger extent — metabolite levels were reduced. 
Consistent with these findings we were unable to show a protective effect 
of MK-801 catecholamine levels in C57 black mice against systemic MPTP, 
employing repeated injection of the N M D A antagonist over two weeks 
and a prolonged survival time (Kupsch et al., 1992). These observations 
prompted us to study the effects of CPP upon M P T P toxicity in C57 black 
mice. In order not to interfere with the pharmacokinetic properties of both 
compounds we chose a survival time of four hours and post-mortem 
biochemical analysis of the striatum, cerebral cortex, brain stem (including 
the substantia nigra) and the cerebellum for D A , 3-methoxytyramine (3-
MT) , D O P A C and H V A as well as serotonin (5-HT) and 5-hydroxy-
indolacetic acid ( H I A A ) content. 
Material and methods 
Animals 
Thirty-two male C57 black mice (Charles River Wiga, Germany), weighing 30-35g 
and housed under standard conditions at a temperature of 22° (±1°C), 50% relative 
humidity and a 12 hour light-dark cycle (light on from 6.00-18.00 h) were allocated to 
four treatment groups. 
Drugs and solutions 
The following compounds were employed: CPP (3-((±)-2-carboxypiperazin-4-yl)-
propyl-l-phosphonic acid, Research Biochemicals, USA), MPTP (l-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine hydrochloride; Schering A G ) dissolved in sterile phy-
siological saline. A l l solutions were prepared immediately before administration and 
injected in a volume of 10ml/kg body weight. A l l dosages refer to the free base. 
Drug treatments and sample preparation 
Groups of eight animals were treated with either vehicle or CPP intraperitoneally 
(25mg/kg i.p.) 30min prior to the intraperitoneal administration of MPTP (20mg/kg 
i.p.) or vehicle. Four hours after administration of MPTP or vehicle the animals were 
sacrificed by decapitation. The brains were quickly removed and cut on an ice-cold 
plate into four regions: 1. the cerebral cortex ("cortex1'), 2. the dopamine-rich part of 
the limbic system (olfactory tubercle, nucleus assumbens) and the striatum ("striatum'1), 
3. the mesencephalon and caudal regions ("brainstem") and 4. the cerebellum. Sam-
ples were weighed, immediately frozen on dry ice and stored at —80°C for biochemical 
analysis. Preparation of samples was performed within five minutes. A l l animal 
experiments were carried out in accordance with the recommendations of the Declara-
tion of Helsinki and the animal welfare guidelines and laws of the Federal Republic of 
Germany. 
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Determination of biogenic amines 
Frozen tissue samples were homogenized in l m l of 0.2 N perchloric acid (10 ml 
containing 200 ul of 10% E D T A and 100 ul of 5% Na 2 S 2 0 5 ) and centrifuged at 30,000 g, 
0°C for 15min. Supernatants and diluted standard solutions were stored at -80°C for 
up two weeks. Analysis of biogenic amines and metabolites was performed using high 
performance liquid chromatography (HPLC) with amperometric detection (elec-
trochemical detector: Gynkotek M20, Pump: Gynkotek M 480, Injector: Gynkotek 
GINA 160, Germany) for simultaneous determination of dopamine, D O P A C (3,4-
dihydroxyphenylacetic acid), H V A (homovanillic acid), 3-MT (3-methoxytyramine), 5-
HT and H I A A . The oxidation potential was set at 690 mV and readings taken at 
0.02nA full scale. Striatal samples were diluted in aliquots of 0.2N perchloric acid 
immediately before injection to allow detection of dopamine under identical detector 
gain. Separation of amines was performed on a C18 reversed-phase column (Inertsil, 
100 x 2 mm, VDS Saulentechnik, Germany) in 10 ul samples. The mobile phase 
consisted of 0.05 M sodiumphasphate buffer, pH 3.7, containing 250mg octansulfonic 
acid and 3% isopropanol in deionized water (Millipore), the flow was set at 90ul/min. 
Quantification was performed on a 386 computer system using integration soft ware 
(PE Nelson Turbochrome 2, USA) employing a three point external standard cal-
bration curve. Raw amounts were corrected for dilution and expressed as amine 
content in pmol per mg wet tissue weight. 
Statistical analysis 
The mean ± S.D. were calculated for monoamine concentrations of the four treatment 
groups in the four brain regions. Statistical differences between groups within one 
region were calculated by one-way analysis of variance ( A N O V A ) followed by post-hoc 
comparisons using the Tukey test (SYSTAT, USA). 
Results 
Administration of CPP resulted in a brief period of stereotyped behaviour 
followed by sedation and a mild hyperthermia. MPTP induced a stimulation 
of locomotor activity lasting 30min and subsequently hypokinesia. Animals 
treated with CPP and M P T P were akinetic throughout the observation 
period. 
The chromatographic system employed here allowed the simultaneous 
determination of dopamine and its principal metabolities D O P A C , H V A 
and 3-MT as well as 5-HT and its metabolite H I A A . Four hours after the 
administration of a single dose of M P T P (20mg/kg i.p.) a more than 60% 
reduction of striatal dopamine and 80% of D O P A C , as compared to vehicle 
or CPP (25mg/kg i.p.) treatment, was observed (cf. Table 1). Pretreatment 
with CPP in combination with MPTP resulted in a 40% reduction of striatal 
dopamine and 60% reduction in D O P A C concentrations. Levels of the two 
remaining dopamine metabolites H V A and 3-MT or the indolamines were 
unchanged. H V A and 3-MT concentrations were not affected in the brain 
stem. However, D O P A C tissue levels were reduced by 70-80% following 
treatment with MPTP plus CPP or CPP, respectively. M P T P alone reduced 
Table 1. Effects of CPP 25 mg/kg i.p. (t = -30min) and MPTP 20mg/kg i.p. alone or in combination upon brain monoamine 
concentrations in C57 black mice 
D A D O P A C H V A 3-MT 5-HT H I A A 
Region/Group [pmol/mg tissue wet weight, Mean (SD), N = 8] 
Striatum 
Vehicle 17.5 (3.1) 2.1 (0.4) 2.5 (1.2) 1.2 (0.5) 4.3 (0.8) 1.4 (0.2) 
CPP 17.1 (3.1) 2.1 (0.4) 2.8 (1.4) 1.1 (0.6) 4.2 (0.8) 1.4 (0.4) 
MPTP 6.5 (1 .5 ) a b c 0.4 (0.2)a-b 
0.9 (0.2) a b 
2.5 (0.8) 1.0 (0.6) 4.3 (0.8) 1.1 (0.2) 
CPP+MPTP 10.9 (2.5) a b 2.2 (1.2) 1.1 (0.3) 4.5 (0.7) 1.3 (0.2) 
Brainstem 
Vehicle 0.6 (0.1) 0.3 (0.09) 0.5 (0.2) 0.07 (0.08) 7.3 (0.7) 3.4 (0.6) 
CPP 0.7 (0.1) 0.4 (0.08) 0.6 (0.2) 0.06 (0.11) 7.5 (0.9) 4.1 (0.7) 
MPTP 0.4 (0.1)b-d 0.05 (0.04) a b 0.4 (0.2) 0.04 (0.02) 9.1 (1.0)d 3.5 (0.4) 
CPP+MPTP 0.5 (0.1) 0.08 (0.05) a b 0.5 (0.2) 0.06 (0.06) 9.5 (1.5) a b 3.3 (0.8) 
Cortex 
Vehicle 2.6 (0.4) 0.4 (0.1) 0.5 (0.2) 0.1 (0.1) 5.2 (0.6) 1.3 (0.3) 
CPP 2.6 (0.3) 0.7 (0.1)a 0.7 (0.2) 0.1 (0.1) 5.0 (0.6) 1.6 (0.3) 
MPTP 1.5 (0.2) a b 0.1 (0.1 ) a b 
0.4 (0.1) a b 
0.5 (0.1) 0.1 (0.1) 5.6 (0.5) 1.2 (0.2) 
CPP+MPTP 1.9 (0.5) a b 0.6 (0.2) 0.2 (0.1) 6.1 (1.0)° 1.2 (0.3) 
Cerebellum 
Vehicle 0.1 (0.04) 0.01 (0.02) 0.04 (0.06) 0.07 (0.2) 1.0 (0.3) 1.0 (0.2) 
CPP 0.1 (0.06) 0.01 (0.02) 0.06 (0.05) 0.04 (0.1) 1.1 (0.4) 1.0 (0.3) 
MPTP 0.1 (0.04) n.d. 0.01 (0.03) n.d. 1.4 (0.3) 0.7 (0.1)c 
CPP+MPTP 0.1 (0.07) n.d. 0.02 (0.05) n.d. 1.6 (0.4) 0.7(0.1)e 
n.d. not detectable; a p < 0.01 vs vehicle; b p < 0.01 vs CPP; c p < 0.05 vs CPP plus MPTP; c ,p < 0.05 vs vehicle; c p < 0.05 vs CPP, 
A N O V A followed by the Tukey test 
dopamine. Both treatments increased 5-HT concentrations by 20-30% in 
this brain region, whereas H I A A was not affected. Similar to the effects of 
both treatments upon striatal dopamine, dopamine and D O P A C levels were 
reduced in the cerebral cortex. CPP alone increased D O P A C and MPTP 
plus CPP increased 5-HT concentrations. There was no effect upon cere-
bellar dopamine. A marked decrease in metabolite concentrations occurred, 
so that D O P A C and 3-MT were not detectable in the MPTP and MPTP 
plus CPP groups. In addition H I A A levels were reduced whereas there was 
no effect upon 5-HT. 
Discussion 
The protective effects of N M D A antagonists in MPTP-induced neuro-
degeneration is still a matter of controversy. The present experiment was 
designed to elucidate acute effects of MPTP and the competitive N M D A 
antagonist CPP in black mice and to compare the present results with a 
study in common marmosets employing a similar treatment schedule of 
MPTP and CPP (Lange et al., 1993). 
Within the terminal regions of DAergic innervation, i.e. the striatum 
and the cerebral cortex, MPTP induced a marked reduction in dopamine 
concentrations. This observation is compatible with the idea of intraneuronal 
M P P + uptake by nerve terminals and fibers but not by somata (Herkenham 
et al., 1991) via the dopamine transporter and subsequent inhibition of the 
mitochondrial respiratory chain. The reduced tissue concentration of 
D O P A C could also indicate inhibitory effects of M P P + upon monoamine 
oxidase (MAO) activity (Feuerstein et al., 1988), because this enzyme is 
located intraneuronally at mitochondrial membranes. The unchanged 
concentrations of 3-MT and H V A in both regions suggest that elimination 
of dopamine occurred without significant effects upon extraneuronal 
catecholamine metabolism since 3-MT is formed from dopamine by the 
extraneuronally located catechol-O-methyltransferase and subsequently 
oxidized by M A O to H V A . This effect of MPTP is only incompletely 
antagonized by pretreatment with CPP because both dopamine and D O P A C 
concentrations are significantly reduced in the group treated with CPP plus 
MPTP. In the brainstem preparation, containing the substantia nigra and 
the ventral tegment as well as the raphe nuclei, the results were different 
with dopamine being significantly reduced by MPTP-treatment alone and 
not affected in the group treated with MPTP and CPP. However, D O P A C 
levels were reduced in both groups. This could indicate that there is indeed 
a regional difference of the effects of MPTP upon catecholamine metabolism 
when competitive N M D A antagonists are present. Within the terminal 
regions CPP is only able to partially protect from dopamine depletion. 
While somata remain principally unaffected, there is a reduction in D O P A C 
formation. In line with this interpretation, we found in common marmosets 
variable effects of CPP upon MPTP-induced striatal catecholamine deple-
tion but a survival of nigral tyrosinehydroxylase (TH) positive neurons 
within the substantia nigra pars compacta at 48 hours following MPTP. 
Thus, these results provide additional evidence for the hypothesis that 
glutamate mediates neurotoxicity, at least at the level of nigral dopaminergic 
somata, and MPTP-induced cell death. 
Although it is still not known how M P T P / M P P + selectively destroys 
DAergic neurons, experimental evidence suggests the involvement of N M D A 
receptor-mediated events in this process. Due to impairment of mito-
chondrial respiration, M P P + could induce a partial membrane depolarisation 
which in turn would remove the voltage-dependent M g 2 + block from 
N M D A receptor ion channels. This would enable E A A s such as glutamate 
to become neurotoxic at physiological concentrations through persistent 
receptor stimulation. The neurotoxicity of MPTP to DAergic terminals was 
not completely prevented by systemic treatment with CPP since the meta-
bolite D O P A C was reduced in the striatum. At the level of DAergic 
somata, however, blockade of N M D A receptors prevents D A depletion. It 
may well be that two processes contribute to MPTP-induced neurotoxicity 
to dopaminergic cells: (i) direct impairment of respiration and metabolism 
in the terminals resulting in the well described retrograde degeneration of 
these cells (Kitt et al., 1987) and (ii) glutamate mediated excitotoxicity 
leading to destruction of the somata in the substantia nigra. Non-
competitive or competitive N M D A antagonists such as MK-801 or CPP 
provide a certain degree of neuroprotection in various models in-vitro and 
in-vivo. However, there are complex pharmacokinetic and pharma-
codynamic interactions between the toxin and putative protective agents 
which complicate the interpretation of results. 
It should be kept in mind, however, that the term neuroprotection is 
used in many different ways. It usually applies only for the experimental 
conditions and/or the measures employed in a given experimental set-up. In 
animal experiments a neuroprotective agent should fulfil the following 
general criteria: 
1. The measure to quantify the effect has to be relevant for the presumed 
clinical situation. 
2. Protection of neurons from degeneration has to be shown at the mor-
phological level. I.e. they should be indistinguishable from intact neu-
rons when stained conventionally, immunohistochemically and using in-
situ hybridisation. 
3. Biochemical measures such as transmitter- and metabolite concentrations 
or enzymatic activities at the level of somata and the projection areas of 
the neurons should be unaffected by the toxin. 
4. Behavioural observation of the experimental animals should show the 
normal repertoire of movements and higher skills. 
5. The protective effect has to be permanent, i.e. survival times should 
control for both the chronic effect of the lesion and the presumed 
protective treatment. 
When taking into account such strict criteria none of the published neuro-
protective strategies, except inhibiton of M A O to block formation of M P P + 
(Heikkila et al., 1984), seems to be effective in antagonizing MPTP-induced 
degeneration. 
In conclusion, the protection from MPTP-mediated neuronal cell death, 
provided by N M D A antagonists, is restricted to nigral DAergic somata. 
Damage to cells occurs by retrograde axonal degeneration due to synpatic 
uptake of the toxin. Pharmacological interference with the pathophysiolo-
gical events subsequent to the inhibition of mitochondrial respiration will 
very probably result in complete protection of the nigrostriatal system. 
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